4572 Carna Biosciences, Inc. - Financial Results

About Information Provided on This Site

The information provided on our website 'Kabutan.com' is not intended to constitute investment solicitation or investment advisory services.
All investment decisions should be made at your own discretion and judgment.
The data on our website is provided by Tokyo Stock Exchange, Osaka Exchange, Nagoya Securities Exchange, JPX Market Innovation & Research, Japannext, and other sources.
Copyright of the Nikkei Stock Average belongs to Nikkei Inc. Stock price charts displayed on Kabutan.com are provided solely for the purpose of reviewing historical price movements of the securities.
These charts neither suggest nor guarantee future price movements of the securities and do not constitute recommendations to buy or sell.
In our financial results coverage, the term 'Surprise Results' identifies securities that demonstrate a significant degree of surprise in their earnings announcements.
This significance is quantitatively assessed based on multiple factors, including: the nature of the announcement (full-year or quarterly results); types of revisions (earnings or dividend forecasts); and numerical analysis comparing the announced results with both the company's previous forecasts and historical performance.
The 'Surprise Ranking' presents these results in order of their calculated surprise factor. Please note that neither these results nor rankings are intended to suggest or guarantee future performance of the listed securities, nor should they be construed as recommendations to buy or sell.

4572

TSE Growth

Carna Biosciences, Inc.

342

JPY

(+0.59%)

Mar 16, 11:30 am JST

2.14

USD

Mar 15, 10:30 pm EDT

Result

PTS

outside of trading hours

340.1

Mar 16, 11:09 am JST

Summary Chart Historical News Financial Result

Current Period Guidance

Annual

Result

Guidance History

Growth Rate

Profitability

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Dec, 2022	1,386	-1,269	-1,278	-1,349	-99.1	0	Feb 10, 2023	J-GAAP
Dec, 2023	1,625	-1,116	-1,126	-1,152	-68.6	0	Feb 9, 2024	J-GAAP
Dec, 2024	636	-2,076	-2,080	-2,178	-121.6	0	Feb 10, 2025	J-GAAP
Dec, 2025	579	-2,074	-2,144	-2,171	-113.6	0	Feb 10, 2026	J-GAAP
Dec, 2026 Guidance	720	-2,028	-2,053	-2,090	-108.9	0	Feb 10, 2026	J-GAAP
YoY	+24.4%	+2.2%	+4.2%	+3.7%	+4.1%

Revision Direction	Revision Date	Revenue	Operating Profit	Ordinary Profit	Net Profit	Revised Dividend	Accounting Standards
Dec, 2021	Feb 12, 2021	923	-1,811	-1,816	-1,825	0	J-GAAP
	Dec 23, 2021	2,006	-548	-552	-560	0	J-GAAP
Results	Feb 10, 2022	2,017	-531	-522	-534	0	J-GAAP
Dec, 2022	Feb 10, 2022	Available in future release
	May 10, 2022
	Dec 14, 2022
Results	Feb 10, 2023
Dec, 2023	Feb 10, 2023
	Dec 14, 2023
Results	Feb 9, 2024
Dec, 2024	Feb 9, 2024
	Dec 19, 2024
Results	Feb 10, 2025
Dec, 2025	Feb 10, 2025
	Dec 18, 2025
Results	Feb 10, 2026
Dec, 2026	Feb 10, 2026	720	-2,028	-2,053	-2,090	0	J-GAAP

Fiscal Year	Revenue	YoY	Operating Profit	YoY	Ordinary Profit	YoY	Adj. EPS	YoY
Dec, 2003	5	－	Available in future release
Dec, 2004	131	+2,520.0
Dec, 2005	209	+59.5
Dec, 2006	405	+93.8
Dec, 2007	513	+26.7
Dec, 2008	499	-2.7
Dec, 2009	687	+37.7
Dec, 2010	571	-16.9
Dec, 2011	592	+3.7
Dec, 2012	510	-13.9
Dec, 2013	771	+51.2
Dec, 2014	611	-20.8
Dec, 2015	1,569	+156.8
Dec, 2016	811	-48.3
Dec, 2017	657	-19.0
Dec, 2018	754	+14.8
Dec, 2019	3,207	+325.3
Dec, 2020	1,133	-64.7
Dec, 2021	2,017	+78.0
Dec, 2022	1,386	-31.3
Dec, 2023	1,625	+17.2
Dec, 2024	636	-60.9
Dec, 2025	579	-9.0
Dec, 2026 Guidance	720	+24.4	-2,028	+2.2	-2,053	+4.2	-108.9	+4.1

Fiscal Year	Revenue	Operating Profit	Operating Profit Margin	ROE	ROA	Total Asset Turnover Ratio	Adj. EPS
Dec, 2024	636	-2,076	-326	-68.58	-61.17	0.18	-121.6
Dec, 2025	579	-2,074	-358	-155.96	-108.52	0.29	-113.6
Dec, 2026 Guidance	720	-2,028	-282	-676.38	-170.06	0.59	-108.9

All-Time High

	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS
Record	3,207	977	957	828	76.1
Fiscal Year	Dec, 2019	Dec, 2019	Dec, 2019	Dec, 2019	Dec, 2019

First Half

Result

Guidance History

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Jan - Jun, 2023	500	-863	-868	-885	-53.8	0	Aug 7, 2023	J-GAAP
Jan - Jun, 2024	315	-1,095	-1,087	-1,094	-63.3	0	Aug 7, 2024	J-GAAP
Jan - Jun, 2025	251	-1,052	-1,055	-1,056	-55.3	0	Aug 6, 2025	J-GAAP
Jan - Jun, 2026 Guidance	ー	ー	ー	ー	－	0	Feb 10, 2026	J-GAAP
YoY	－	－	－	－	－

Revision Direction	Revision Date	Revenue	Operating Profit	Ordinary Profit	Net Profit	Revised Dividend	Accounting Standards
Jun, 2023	Feb 10, 2023	ー	ー	ー	ー	0	J-GAAP
- - - - Results	Aug 7, 2023	500	-863	-868	-885	0	J-GAAP
Jun, 2024	Feb 9, 2024	Available in future release
Results	Aug 7, 2024
Jun, 2025	Feb 10, 2025
Results	Aug 6, 2025
Jun, 2026	Feb 10, 2026	ー	ー	ー	ー	0	J-GAAP

Cash Flow

Annual

Fiscal Year	Operating Profit	Fee Cash Flow	Operating Cash Flow	Investing Cash Flow	Financial Cash Flow	Cash & Equivalents	Cash Ratio	Accounting Standards
Dec, 2023	-1,116	-1,688	-1,677	-11	1,182	2,889	66.43	J-GAAP
Dec, 2024	-2,076	-1,387	-1,374	-13	567	2,108	76.05	J-GAAP
Dec, 2025	-2,074	-2,184	-2,159	-25	604	516	41.99	J-GAAP

Actual Performance and Financial Trends

Historical Performance

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Dec, 2023	1,625	-1,116	-1,126	-1,152	-68.6	0	Feb 9, 2024	J-GAAP
Dec, 2024	636	-2,076	-2,080	-2,178	-121.6	0	Feb 10, 2025	J-GAAP
Dec, 2025	579	-2,074	-2,144	-2,171	-113.6	0	Feb 10, 2026	J-GAAP
YoY	-9.0%	+0.1%	-3.1%	+0.3%	+6.6%

Quarterly Results

Result

Growth Rate

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Operating Profit Margin	Announce	Accounting Standards
Jan - Mar, 2024	180	-416	-394	-398	-23.3	-231.1	May 10, 2024	J-GAAP
Apr - Jun, 2024	135	-679	-693	-696	-40.2	-503.0	Aug 7, 2024	J-GAAP
Jul - Sep, 2024	172	-483	-492	-494	-28.2	-280.8	Nov 8, 2024	J-GAAP
Oct - Dec, 2024	149	-498	-501	-590	-33.0	-334.2	Feb 10, 2025	J-GAAP
Jan - Mar, 2025	143	-497	-498	-499	-26.1	-347.6	May 9, 2025	J-GAAP
Apr - Jun, 2025	108	-555	-557	-557	-29.2	-513.9	Aug 6, 2025	J-GAAP
Jul - Sep, 2025	144	-499	-535	-544	-28.5	-346.5	Nov 7, 2025	J-GAAP
Oct - Dec, 2025	184	-523	-554	-571	-29.9	-284.2	Feb 10, 2026	J-GAAP
YoY	+23.5%	-5.0%	-10.6%	+3.2%	+9.3%

Fiscal Year	Revenue	YoY	Operating Profit	YoY	Ordinary Profit	YoY	Adj. EPS	YoY
Jan - Mar, 2021	231	-31.0	Available in future release
Apr - Jun, 2021	199	-18.4
Jul - Sep, 2021	206	-23.1
Oct - Dec, 2021	1,381	+382.9
Jan - Mar, 2022	554	+139.8
Apr - Jun, 2022	285	+43.2
Jul - Sep, 2022	256	+24.3
Oct - Dec, 2022	291	-78.9
Jan - Mar, 2023	226	-59.2
Apr - Jun, 2023	274	-3.9
Jul - Sep, 2023	211	-17.6
Oct - Dec, 2023	914	+214.1
Jan - Mar, 2024	180	-20.4
Apr - Jun, 2024	135	-50.7
Jul - Sep, 2024	172	-18.5
Oct - Dec, 2024	149	-83.7
Jan - Mar, 2025	143	-20.6
Apr - Jun, 2025	108	-20.0
Jul - Sep, 2025	144	-16.3
Oct - Dec, 2025	184	+23.5	-523	-5.0	-554	-10.6	-29.9	+9.4

All-Time High Quarterly Results

	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS
Record	2,291	1,684	1,681	1,431	136.4
Fiscal Year	Jun, 2019	Jun, 2019	Jun, 2019	Jun, 2019	Jun, 2019

Key Balance Sheet Figures

Fiscal Year	BPS	Equity Ratio	Total Asset	Equity	Retained Earnings	Interest-Bearing Debt Ratio	Announce	Accounting Standards
Dec, 2023	226.16	89.1	4,349	3,877	-4,075	0.05	Feb 9, 2024	J-GAAP
Dec, 2024	129.62	89.3	2,772	2,475	-6,253	0.02	Feb 10, 2025	J-GAAP
Dec, 2025	16.16	25.1	1,229	309	-1,980	2.31	Feb 10, 2026	J-GAAP

Carna Biosciences, Inc.(4572) Financial Results